Period:
Draw Mode:
| Volume | 11,292 |
|
|||||
| News | - | ||||||
| Day High | 1.33 | Low High |
|||||
| Day Low | 1.30 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Panbela Therapeutics Inc | PBLA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.04 | 3.12% | 1.32 | 14:36:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.32 | 1.30 | 1.33 | 1.28 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 185 | 11,292 | $ 1.31 | $ 14,802 | - | 1.21 - 453.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:53:11 | 1 | $ 1.33 | USD |
Panbela Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.9M | 2.96M | - | 0 | -34.93M | -11.81 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Panbela Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PBLA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.33 | 1.37 | 1.21 | 1.27 | 26,032 | -0.01 | -0.75% |
| 1 Month | 1.35 | 1.54 | 1.21 | 1.42 | 74,190 | -0.03 | -2.22% |
| 3 Months | 2.19 | 3.07 | 1.21 | 2.11 | 946,527 | -0.87 | -39.73% |
| 6 Months | 15.252 | 23.85 | 1.21 | 11.64 | 1,762,820 | -13.93 | -91.35% |
| 1 Year | 435.00 | 453.60 | 1.21 | 87.16 | 3,276,070 | -433.68 | -99.7% |
| 3 Years | 4,080.00 | 10,560.00 | 1.21 | 290.37 | 1,270,960 | -4,078.68 | -99.97% |
| 5 Years | 4,080.00 | 10,560.00 | 1.21 | 290.37 | 1,270,960 | -4,078.68 | -99.97% |
Panbela Therapeutics Description
| Panbela Therapeutics Inc is a clinical stage drug development company. It is engaged in the commercial development of a proprietary polyamine analogue for pancreatic cancer and for the second indication in chronic pancreatitis. The firm has developed a polyamine analogue compound referred as SBP-101 for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. |